- Home
- LTRN vs SLGL Comparison
LTRN vs SLGL Comparison
Compare LTRN & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LTRN | SLGL |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.9M | 117.8M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LTRN | SLGL |
|---|---|---|
| Price | $3.31 | $42.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $25.00 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 73.5K | 14.2K |
| Earning Date | 11-12-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,970,000.00 |
| Revenue This Year | N/A | $121.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $2.55 | $4.02 |
| 52 Week High | $6.12 | $52.26 |
Technical Indicators
Market Signals| Indicator | LTRN | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 40.17 | 55.90 |
| Support Level | $3.19 | $39.26 |
| Resistance Level | $3.49 | $44.04 |
| Average True Range (ATR) | 0.26 | 3.07 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 9.88 | 66.20 |
Price Performance
Historical ComparisonAbout LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.